The study evaluates whether long-term treatment with colchicine reduces rates of
cardiovascular events in patients after myocardial infarction. Patients who have suffered a
documented acute myocardial infarction within the last 30 days, are treated according to the
national guidelines and after having completed any planned percutaneous revascularization
procedures associated with their initial infarction will receive either colchicine (0.5 mg
per day) or matching placebo (1:1 allocation ratio) for an estimated 2 years period or until
the target of 301 primary endpoints has been reached.